Biobrace Augmentation for Kneecap Dislocation
(BioPPD Trial)
Trial Summary
What is the purpose of this trial?
This study aims to determine the ability of medial patellofemoral ligament (MPFL) repair augmented with Biobrace® to decrease the re-dislocation rate after a primary patellofemoral dislocation. First-time patellofemoral dislocation is a significant problem, and the ramifications of recurrence for patients are substantial. Due to the multifactorial nature of the pathoanatomy of patellofemoral instability, it has been difficult to design trials that will show how interventions could affect the natural history of these young patients. No definitive studies have determined whether the surgical reconstruction of the MPFL in patients with mild to moderate pathoanatomic risk factors will decrease the re-dislocation rate after a first-time dislocation. In addition, to date, no synthetic option has provided both biology and strength for ligament augmentation. This innovation may allow for a minimalist approach to keeping the patella centred in the trochlear groove during the healing phase after a first-time dislocation.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators or your doctor for guidance.
What data supports the effectiveness of the treatment Biobrace Augmentation for kneecap dislocation?
How does Biobrace Augmentation treatment for kneecap dislocation differ from other treatments?
Biobrace Augmentation is unique because it uses a bioinductive scaffold made of type I collagen and bioresorbable microfilaments to support tissue regeneration and provide mechanical support, which is different from traditional surgical repairs that may not use such materials. This approach aims to enhance the natural healing process and potentially speed up rehabilitation compared to standard treatments.46789
Research Team
Laurie A Hiemstra, MD, PhD
Principal Investigator
University of Calgary
Eligibility Criteria
This trial is for individuals aged 13-30 who have experienced their first kneecap dislocation within the last week. Participants must have growth plates that are closed or nearly closed, as confirmed by knee x-rays.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo knee arthroscopy and MPFL repair augmented with Biobrace® synthetic ligament
Post-operative Monitoring
Patients are monitored for pain and medication use in the initial 14 days post-operative
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 6, 12, and 24 months post-operative
Treatment Details
Interventions
- Biobrace Augmentation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Banff Sport Medicine Foundation
Lead Sponsor
CONMED Corporation
Industry Sponsor